Advanced Search

 

Study ID Status Title Patient Level Data
SUM40299 Completed A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of oral sumatriptan 25mg, 50mg, and 100mg tablets for a single moderate or severe headache in adults diagnosed with migrainous disorder International Headache Society (IHS) 1.7. Study Listed on ClinicalStudyDataRequest.com
SUM40301 Completed An open-label evaluation of patient satisfaction with IMITREX (sumatriptan succinate) tablets, 100mg, administered at the first sign of pain for up to three migraines in patients who are not satisfied with their current triptan therapy. Study Listed on ClinicalStudyDataRequest.com
SUM40304 Completed A randomised, double-blind, placebo controlled, cross-over clinical trial to investigate the relation of migraine recurrence and anxiety-depressive symptoms in patients treated with Sumatriptan.
SUM40308 Completed A Danish, randomised, multicentre, comparative, parallel-group study of the effect of sumatriptan 50mg versus placebo in migraine patients with 6 to 11 attacks per year, taken during the mild phase of a migraine attack.
SUM40310 Completed A randomised, open, parallel-group study comparing intake of sumatriptan 100mg tablets at the first signs of migraine pain versus intake at moderate to severe headache during an acute migraine attack.
SUM40311 Completed A randomized, double-blind, placebo-controlled, single-attack, parallel-group evaluation of the efficacy of sumatriptan 100mg tablets versus placebo in the treatment of self-described and/or physician-diagnosed sinus headaches that meet International Headache Society (IHS) criteria for migraine ...
SUM40312 Completed A Randomized, Double-Blind, Placebo-Controlled, Single-Attack, Parallel-Group Evaluation of the Efficacy of Sumatriptan 100mg Tablets versus Placebo in the Treatment of Subjects who Affirm Tension, Tension-Type or Stress Headaches and who meet International Headache Society (IHS) Criteria for Migraine. Study Listed on ClinicalStudyDataRequest.com
SUMA2002 Completed A randomized, double-blind, placebo-controlled study of the safety and efficacy of 25mg, 50mg and 100mg oral sumatriptan in adolescent migraine subjects.
SUMA3005 Completed A double-blind. placebo-controlled, parallel group study to evaluate three dose levels (5mg, 10mg and 20mg) of sumatriptan nasal spray in the acute treatment of a single migraine attack in adolescent migraineurs (12-17 years of age).
SUMA3006 Completed An open-label study to evaluate the long-term safety, tolerability and efficacy of sumatriptan nasal spray in the acute treatment of multiple migraine attacks in adolescent migraineurs (12-17 years of age).
SUMA4004 Completed A randomized, double-blind, placebo-controlled study to evaluate the impact of Imitrex® injection on work place productivity loss due to migraine.Imitrex is a registered trademark of the GlaxoSmithKline group of companies.
SUMA4014 Completed A Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of a Second Sumatriptan Succinate Tablet (25 or 50mg) in the Acute Treatment of Migraine.
SUMA4015 Completed A randomised, double-blind, placebo-controlled study to evaluate the impact of sumatriptan injection on work place productivity loss due to migraine.
SUMA4016 Completed A Randomized, Double-Blind, Double-Dummy, Active-Placebo Controlled, Parallel Group Evaluation of Oral Sumatriptan (50mg) Compared to Oral Naproxen Sodium (275mg) on Migraine-Related Quality of Life.
SUMA4017 Completed A Randomized, Double-Blind, Double-Dummy, Active-Placebo Controlled, Parallel Group Evaluation of Oral Sumatriptan (50mg) Compared to Oral Naproxen Sodium (275mg) on Migraine-Related Quality of Life.
SUMAI 01 Completed An open 6-month-study for the treatment of acute migraine attacks with sumatriptan (6 mg subcutaneous (sc). plus optional 6 mg sc) using an autoinjector, complemented by a) the possibility to prolong the study up to 18 months in total; and/or complemented by b) the possibility to assess quality ...
SUMAI CH Completed An open 12-month study for the acute treatment of cluster headache attacks with sumatriptan using an autoinjector.
SUMB1006 Completed An open, uncontrolled study to investigate the single dose pharmacokinetics of sumatriptan nasal spray in adolescent subjects with migraine outside of a migraine attack.
SUMB2001 Completed A double-blind, randomised, placebo-controlled study to investigate the neuroendocrine response to repeat-dose oral sumatriptan in adolescent migraineurs.
SUMB2003 Completed A double-blind, randomised, placebo-controlled study to compare the efficacy and safety of oral sumatriptan (25mg, 50mg and 100mg) in the acute treatment of migraine in adolescents.
SUMB3002 Completed A double-blind, placebo-controlled, parallel-group study to evaluate two dose levels (10mg and 20mg) of sumatriptan nasal spray in the acute treatment of a migraine attack with an optional repeat dose for headache recurrence.
SUMB3005 Completed An open-label study to evaluate repeat-dose oral sumatriptan 100mg in the acute treatment of adolescent migraine during a six month period.
SUMB4002 Completed A double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of a 6mg sc dose of sumatriptan in patients who have not responded to acute treatment of a migraine attack with 100mg oral dose of sumatriptan.
SUMB4007 Completed A double-blind, parallel group study to compare the benefits of 100mg and 50mg oral sumatriptan in patients dissatisfied with the relief of their migraine symptoms following open-label treatment with 50mg oral sumatriptan.
SUMT40 Completed A crossover study to evaluate the efficacy and tolerability between sumatriptan suppository 25mg and sumatriptan tablet 50mg in the treatment of acute migraine (with and without aura) associated with the menstrual cycle.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.